This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Escudier B et al. (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 23 (Suppl): 4510
Acknowledgements
The synopsis was written by Carol Lovegrove, Freelance Medical Writer.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Klein, E. Promise for patients with metastatic renal cell carcinoma. Nat Rev Urol 4, 72–73 (2007). https://doi.org/10.1038/ncpuro0704
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0704